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Background:Warfarin directly inhibits vitamin K 2,3-epoxide reductase (VKOR) enzymes. Since the early 1970s,
warfarin inhibition of vitamin K 2,3-epoxide reductase complex subunit 1 (VKORC1), an essential enzyme for
proper function of blood coagulation in higher vertebrates, has been studied using an in vitro dithiothreitol
(DTT) driven enzymatic assay. However, various studies based on this assay have reported warfarin dose–
response data, usually summarized as half-maximal inhibitory concentration (IC50), that vary over orders of
magnitude and reﬂect the broad range of conditions used to obtain VKOR assay data.
Methods: We standardized the implementation of the DTT-driven VKOR activity assay to measure enzymatic
Michaelis constants (Km) and warfarin IC50 for human VKORC1. A data transformation is deﬁned, based on
the previously conﬁrmed bi bi ping-pong mechanism for VKORC1, that relates assay condition-dependent
IC50 to condition-independent Ki.
Results: Determination of the warfarin Ki speciﬁcally depends on measuring both substrate concentrations, both
Michaelis constants for the VKORC1 enzyme, and pH in the assay.
Conclusion: The Ki is not equal to the IC50 value directly measured using the DTT-driven VKOR assay.
General signiﬁcance: In contrast to warfarin IC50 values determined in previous studies, warfarin inhibition
expressed as Ki can now be compared between studies, even when the speciﬁc DTT-driven VKOR assay
conditions differ. This implies that warfarin inhibition reported for wild-type and variant VKORC1 enzymes
from previous reports should be reassessed and new determinations of Ki are required to accurately report
and compare in vitro warfarin inhibition results.© 2013 The Authors. Published by Elsevier B.V. All rights reserved.1. Introduction
Warfarin, originally developed in the 1940s and applied at high
dosages as a pesticide to cause hemorrhaging in rats and mice, was
introduced for use in humans at lower dosage in the 1950s as pro-
phylaxis and treatment for thromboembolic conditions. Since 1960,
when genetically inherited resistance to warfarin was ﬁrst reported,3-epoxide reductase; VKORC1,
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blished by Elsevier B.V. All rights refor wild rodents exposed to the rodenticide in broadcast pest control
strategies [1], early studies of the pharmacological and biological
effects of warfarin commenced in live animals [2,3]. Subcellular frac-
tionation methods showed that warfarin binding is localized to mi-
crosomal preparations comprising ER membranes from liver cells.
Thus, investigators adopted microsomal preparations as the standard
system for studying the effects of warfarin on various enzymatic activi-
ties involved in vitamin K-dependent clotting factor biosynthesis and
activation including, among others, the warfarin-sensitive vitamin K
2,3-epoxide reductase (VKOR) activity [4,5]. For years, however, prog-
ress in the study of VKOR enzymatics was impeded by the fact that
the warfarin-sensitive VKOR activity ran down over time, limiting the
ability to follow kinetic time courses of enzymatic processes over
more than a few minutes [6]. In 1976, Friedman & Shia and Mack et al.
found that warfarin-sensitive VKOR activity could be sustained for
longer time by reduction of enzyme-intrinsic thiols by the non-
physiological reductant dithiothreitol (DTT) [7,8]. By 1978, Whitlon
et al. found that DTT, together with either vitamin K1 (K1) or vitaminserved.
4203C.G. Bevans et al. / Biochimica et Biophysica Acta 1830 (2013) 4202–4210K1 2,3-epoxide (K1>O), could drive sustained in vitro warfarin-
sensitive VKOR-dependent production of active clotting factors in
microsomal preparations [9]. The possibility of using this basic
assay to measure VKOR enzymatic activity and dose–response inhi-
bition data for warfarin was quickly recognized and, indeed, invoked
in a number of subsequent studies (c.f. [10–13]). Although satura-
ble, high afﬁnity binding of warfarin to the enzyme has been previ-
ously demonstrated, presently it is not known if warfarin inhibits
VKORC1 reversibly or irreversibly [5].
With the discovery of the gene and protein sequences for human
and rat VKORC1 enzymes in 2004, an intriguing paradox was revealed
by Rost et al. They found that although the DTT-driven in vitro VKOR ac-
tivity assay revealed an expected dose-dependent response forwarfarin
inhibition of wild-type VKORC1, it failed to report the expected shift
in dose–response data to higher warfarin concentrations for the ﬁrst
four identiﬁed single-residue VKORC1 missense variants associated
with in vivowarfarin resistance in humans [14,15]. Since the initial re-
port of these paradoxical results, only seven (humanVKORC1: Ala26Pro,
Val54Leu, Ile123Asn, Tyr139His; ratVKORC1: Tyr139Phe, Ala143Val;
mouseVKORC1: Ala48Thr) of the more than 60 identiﬁed naturally
occurring human, rat and mouse warfarin-resistant VKORC1 missense
variants have been shown to exhibit in vitro warfarin resistance by
the DTT-driven VKOR assay [16–21]. Additionally, six other rodent
VKORC1 variants (ratVKORC1: Leu120Gln, Leu128Gln, Tyr139Cys,
Tyr139Ser; mouseVKORC1: Ala26Ser, Tyr139Cys) associated with
in vivo warfarin resistance phenotypes exhibit resistance only at
very high (≥60 μM), but not at lower, warfarin concentrations by
the DTT-driven assay [19]. Of even more fundamental concern are
the aggregate results from previously published studies that reveal
warfarin dose–response data, determined using the DTT-driven VKOR
assay, with half-maximal inhibition concentration (IC50) values that
range over an order of magnitude for the wild-type human and rat
VKORC1 enzymes. A review of the literature since 2004, when VKORC1
was ﬁrst identiﬁed and expressed, reveals warfarin inhibition datamea-
sured by the DTT-driven VKOR assay ranging from 0.5 μM to 4 μM
(Table S1, online Supplemental Information) [14–25]. Additionally, the
range of warfarin IC50 values is even greater when assessed by cell cul-
ture systems expressing VKORC1 (24.7 nM to 4 μM; see Table S1)
[26–29]. Taken together, the greater than two order-of-magnitude
range in published warfarin IC50 values suggests that some important
aspects of the assay systems are not understood. Interestingly, some of
the previously published DTT-driven assay studies reported measure-
ments of the enzyme-intrinsic Ki for warfarin inhibition, but these stud-
ies assumed an enzymatic kinetic model for VKORC1 with only one
substrate—vitamin K 2,3-epoxide (K>O) [21,25].
Details of the precise relationships between assay-dependent
IC50 values and assay-independent Ki values for various enzymatic
reactions have been previously explored in a classic report by
Cheng & Prusoff who pointed out that detailed information about
the inhibitorymechanism together with the speciﬁc assay conditions
used are essential for properly interpreting the experimental data
and for comparing data between studies [30]. For enzymes with
only single substrates, the IC50 value will approach that of Ki at sub-
strate concentrations much greater than the Michaelis constant
(Km). Practically, this condition can be achieved by ensuring that ini-
tial substrate concentration is one or more orders of magnitude
greater than Km. In contrast to single-substrate enzymes, VKORC1 re-
quires a second substrate—DTT—which undergoes enzymatic oxida-
tion to supply reducing equivalents for conversion of K>O to the
vitamin K quinone form. For enzymes with two substrates, IC50 will
generally be related to Ki by an enzyme kinetic model-speciﬁc func-
tion of both substrate concentrations used in the enzymatic assay
and of the speciﬁc type of inhibition. In the current study we show
that speciﬁc inhibition mechanism, accurately determined Michaelis
constants and substrate concentrations used in the assay are re-
quired in order to deﬁne the functional relationship between IC50and Ki. Rat and bovine VKORC1 kinetic data from in vitro enzymatic
studies were consistent with a proposed bi bi ping-pong mechanism
[13,31]. Additionally, warfarin inhibition of VKORC1 was found to be
non-competitive with respect to the K>O substrate, but competitive
for the DTT substrate [9,32]. Human VKORC1 shares over 80% prima-
ry sequence identity with the rat and bovine enzymes, strongly
suggesting a common bi bi ping-pong mechanism.
Here, we resolve the nearly decade-old Rost et al. paradox by
demonstrating that warfarin IC50 values must be transformed to Ki
constants in order to assess warfarin inhibition independently of the
speciﬁc conditions used in the DTT-driven VKOR assay.
2. Materials and methods
2.1. Chemicals & reagents
Racemic warfarin free acid and vitamin K1 (phylloquinone) were
purchased from Sigma-Aldrich Chemie GmbH (Munich, Germany).
Vitamin K1-2,3-epoxide (K1>O) was prepared according to Tishler
et al. [33]. Concentrations of vitamin K quinone (100 μM) and K>O
(400 μM) stock solutions in ethanol were conﬁrmed by UV ab-
sorption using molar extinction coefﬁcients of 18,900 M−1cm−1 at
249 nm and 30,800 M−1 cm−1 at 266 nm, respectively. All other re-
agents were standard grade (p.a.) purchased from Sigma-Aldrich
Chemie GmbH. HPLC-grade methanol was from Carl Roth GmbH &
Co. KG (Karlsruhe, Germany).
2.2. Production of human VKORC1 in Pichia pastoris
We created amodiﬁed Invitrogen™ pPIC9K P. pastoris expression vec-
tor that is optimized for membrane protein production [34]. This vector
encodes (5′- to 3′-order): N-terminal α-mating factor from S. cerevisiae,
ﬂag-tag epitope, his10-tag, Tev protease cleavage site, multiple cloning
site, C-terminal Tev cleavage site, EGFP, Strep-tag II. The human
VKORC1 DNA sequence was inserted into the multiple cloning site and
modiﬁed using the Stratagene QuikChange® Multi Site-Directed Muta-
genesis Kit (Agilent Technologies GmbH& Co. KG,Waldbronn, Germany)
to introduce site-directed mutations VKORC1:K152Q, R162Q and EGFP:
R216Q (removing internal P. pastoris Kex2 protease cleavage sites) and
EGFP:A207K (preventing EGFPdimerization)[35] (see online Supplemen-
tary Information for the veriﬁed sequence, hereafter simply referred to as
VKORC1). The veriﬁed expression construct was electroporated into
histidine auxotrophic P. pastoris strain SMD 1168 Kex1− (multiple
protease-deﬁcient). Positive transformants were selected on minimal
dextrose (MD) agarose plates (1.34% yeast nitrogen base without amino
acids, 2% dextrose, 0.00004% biotin, 1.5% agar). Subsequently, selection
for best expressing clones was by screening for G418 hyperresistance
(YPD agar plates with 0.05–0.5 mg/mL G418, 1% yeast extract, 2% pep-
tone, 2% dextrose, 2% agar) followed by expression level assessment in
small-scale cultures [34].
Two 1 L Pichia pre-cultures were grown in BMGYmedium (1% yeast
extract, 2% peptone, 1.34% yeast nitrogen base without amino acids,
0.00004% biotin, 1% glycerol, 0.1 M phosphate buffer pH 6) in 5 L baf-
ﬂed shaker ﬂasks at 30 °C, ~130 rpm for maximal aeration, to a ﬁnal
OD600 nm of 6.0. Cells were harvested by centrifugation (3000 ×g,
5 min) and equally resuspended into twelve 1 L BMMY expression cul-
tures (same as BMGY, but with 0.5% initial methanol concentration
instead of glycerol) in 5 L bafﬂed ﬂasks (starting OD600nm was 1.0), in-
cubated at 30 °C, ~130 rpm for maximal aeration. Expression cultures
were induced for 24 h with addition of methanol to 0.5% ﬁnal concen-
tration again after 12 h. Total yield was ~200 g wet cell mass.
2.3. Preparation of ER membranes enriched for VKORC1
Cells were harvested in 1 L centrifuge bottles at 3000 ×g for 15 min,
resuspended in 4 °C breaking buffer (50 mM sodium phosphate,
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all subsequent processing of sample at 4 °C) and broken by passage
through a Desintegrator C glass bead mill (Bernd Euler Biotechnologie
Mikrobiologie, Frankfurt/Main, Germany) until >90% of cells were
broken as assessed by phase contrast light microscopy at 400× magni-
ﬁcation. Bead mill-processed cell slurry was centrifuged at 3000 ×g,
15 min to remove unbroken cells and debris, layered onto sucrose
step gradients, centrifuged to separate the ER membrane-rich frac-
tion (Fig. S1; see also online Supplementary Methods). The
VKORC1-enriched membranes were collected and centrifuged three
times followed each time by resuspension using a tight-ﬁtting glass
dounce homogenizer to exchange the membranes into storage buffer
(10 mM HEPES, pH 7.6, 10 mM NaCl, 0.02% (w/v) NaN3). ER-enriched
membranes (total mass determined by vacuum drying to constant
weight) were ﬁnally resuspended to 16.7 mg/mL in storage buffer, dis-
pensed into 60 μL aliquots each containing 1 mg dry mass membranes,
and ﬂash-frozen in liquid nitrogen for storage at −80 °C until fur-
ther use. Final yield was approximately 2 g (dry mass equivalent) of
ER-enriched membranes in 120 mL with a total VKORC1 protein yield
of 3 mg as assessed by EGFP ﬂuorescence (λexcitation 489 nm, λemmision
510 nm) of samples diluted into storage buffer measured at 20 °C
using a Hitachi F-4500 FL ﬂuorescence spectrophotometer (Hitachi
High-Technologies Europe GmbH, Mannheim, Germany).
2.4. In vitro DTT-driven VKOR assay
Standardized DTT-driven VKOR assay samples contained (added in
the order listed): 495 μL Buffer B (25 mM imidazole, pH 7.6, 0.5%
(w/v) CHAPS), 5 μL Pichia ER-enriched membranes (83.3 μg dry
mass) containing 125 ng expressed VKORC1 construct protein in
storage buffer (10 mM HEPES, pH 7.5, 10 mM NaCl), 5 μL 400 mM
CaCl2 in Buffer B, 5 μL of various warfarin concentrations in ethanol
(or 5 μL ethanol blank for 0 μMwarfarin), 10 μL K1>O at various con-
centrations in ethanol, 20 μL of either 5 or 0.5 mM DTT dissolved in
Buffer B. VKORC1 enzyme concentration in assay samples was
4.5 nM. We collected data for seven different warfarin ﬁnal concen-
trations in the mid-nanomolar to almost millimolar range (0 nM,
85.4 nM, 787.3 nM, 3.797 μM, 7.089 μM, 76.8 μM, 412.9 μM; all
concentrations determined by absorbance spectroscopy to values of
four signiﬁcant ﬁgures using ε = 1122 M−1 cm−1 at λ = 271 nm).
Assay constituents were pipetted into 2 mL glass vials (500X2CVP620,
Chromacol Ltd., U.K.) with vortex mixing at low speed after each addi-
tion except for high-speedmixing after addition of DTT and application
of a teﬂon-lined crimped cap (500X11-AC-ST15703, Chromacol Ltd.,
U.K.). Assay reaction was run for 60 min, 30 °C in the dark. After
reaction, samples were rapidly uncapped, 1 mL of 3:2 volume ratio
isopropanol:hexane was added, vials crimp-capped, shaken by hand
and vortexed at full speed for ~15 s, brieﬂy centrifuged at 3000 ×g to
separate organic and aqueous phases, unsealed, and 200 μL of the
organic (upper) phase transferred to small volume V-shaped glass
vials (500X03-FIVC706, Chromacol Ltd., U.K.). Organic solvent was re-
moved by vacuum drying for 30 min before adding 75 μL HPLC-grade
methanol and crimp-capping vials.
2.5. HPLC and spectrophotometric analysis of VKOR reaction products
VKOR assay samples in glass V-bottom vials were transferred to
the autosampler of a Merck-Hitachi LaChrom Elite® HPLC system with
column oven set to 30 °C and outﬁtted with a diode array detector
(VWR International GmbH, Darmstadt, Germany). Sample separation
was achieved using a Spherisorb® ODS-1 column (5 μm particle size,
250 mm × 4.6 mm i.d.) reverse phase column with a Spherisorb®
ODS-1 guard pre-column (Grace—Alltech GROM GmbH, Rottenburg-
Hailﬁngen, Germany); isocratic methanol elution at 1 mL/min. Vitamin
K quinone, vitamin K 2,3-epoxide and endogenous Pichia ubquinone-8
peaks were quantiﬁed by absorbance at 248 nm using the EZChromElite™ software package. Integrated vitamin K quinone and epoxide
peak signals were normalized to the endogenous Pichia ubiquinone-8
peak signal as internal standard to compensate for pipetting errors.
2.6. Warfarin dose–response curve ﬁtting and IC50 value analysis
VKOR enzymatic activity was calculated as the percent conversion of
K>O substrate to K product for each sample from the ubquinone-8
internal standard-normalized data. The VKOR activity level in the
absence of warfarin was assigned a value of 100% and all warfarin inhibi-
tion data were normalized to this value. Final warfarin concentrations in
the assay samples were 0, 0.0854, 0.7873, 3.797, 7.089 or 412.9 μM; for
the dose–response data using 0.296 μM K1>O and 5 mM DTT at pH 7.5,
an additional ﬁnal warfarin concentration of 76.75 μMwas used to obtain
additional data nearer to the apparent IC50 value to increase accuracy in
curve ﬁtting. Three separate samples (N = 3) were run in parallel for
each assay condition; mean values and SEM were calculated and
plotted for each of three warfarin dose–response series measured
at 0.5 and 5 mM DTT with 0.977 μM K1>O and at 5 mM DTT with
0.296 μM K1>O. Best-ﬁt 4 parameter dose–response curves were ﬁt
to mean values for both data sets using the automated Levenberg–
Marquardt non-linear least squares algorithm of KaleidaGraph
version 4.04 software (Synergy Software, Reading, PA, USA).
Half-maximum inhibitory concentrations for warfarin (IC50) were
calculated by solving the 4 parameter dose–response equation (see
below) for the independent variable as a function of the dependent
variable and substituting a dependent value of 50 since VKOR activ-
ities were normalized to 100% in the absence of warfarin inhibitor
(see Supplementary Methods and Table S1 of the online Supplemen-
tal Information). R2 correlation values were calculated to indicate
goodness of ﬁt for the dose–response curves. Ki values were calculat-
ed from Eq. (1) (see Section 4.1 for the complete derivation):







where experimentally determined values include [DTT] the concen-
tration of DTT substrate, [K>O] the concentration of vitamin K
2,3-epoxide substrate, Km,DTT and Km,K>O the Michaelis constants
for substrates DTT and K>O, respectively, and IC50 determined by
curve-ﬁtting as described above.
3. Results
3.1. Determination of Michaelis constants for K1>O and DTT
thiolate substrates
For various substrate concentrations ranging from 0.069 μM to
1.41 μM K>O and from 0.1 mM to 20 mM DTT at pH 7.5 (equivalent
thiolate concentration range of 2.2–449.3 μM),wemade three indepen-
dent measurements (N = 3) of VKORC1 enzymatic activity monitored
as K1 product produced during the linear phase of the VKOR assay reac-
tion over 60 min. To ensure minimal K1 product inhibition, or product
competition for the vitamin K reductase activity also catalyzed by
VKORC1 [23], we included only data for which K1 product did not
exceed 5% of the initial K1>O substrate concentration. Accordingly,
data for K>O concentrations of 0.977 μM and 1.41 μM and for
DTT concentrations of 0.5 mM and 1.0 mM at pH 7.5 were used for
Michaelis constant determinations (Tables S2, S3 of the online
Supplemental Information). By Eisenthal & Cornish-Bowden direct
linear plot analysis, the Michaelis constant for K>O (Km,K1>O) for
the human VKORC1 construct in P. pastoris ER membranes was
1.24 μM at a DTT concentration of 0.5 mM and pH 7.5 (equivalent
to 11.23 μM thiolate, ~1/18-fold Km,thiolate). The Michaelis constant
for DTT thiolate (Km,thiolate) for the same VKORC1 construct and
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pH 7.5) at a K1>O concentration of 20 μM (i.e., >16-fold Km,K1>O).
3.2. VKOR enzymatic activity of human VKORC1 is maximal between
pH 6.0 and 7.0 and is not Ca2+-dependent
The results presented in Fig. 1A show that there is no signiﬁcant
difference for DTT-driven VKOR activity in either the presence of
3.7 mM Ca2+ or 0.5 mM EGTA (i.e., in the complete absence of
Ca2+) for the human VKORC1 construct when substrate concentra-
tions were 0.977 μM K1>O and 0.5 mM DTT, pH 7.5 (equivalent to
11.23 μM thiolate). To initially survey the pH-dependence of VKOR
activity for VKORC1 uncomplicated by the pH-dependent dissociation
of DTT to thiolate, we made use of the Henderson–Hasselbalch
equaton to calculate amounts of DTT required to yield 22.5 μM dissoci-
ated thiolate at each pH level. Using a K1>O substrate concentration of
0.977 μM yielding mean K1 product levels of 5.6% ± 0.2%(SEM) with
respect to K1>O substrate levels during the assay, results for three inde-
pendent measurements (N = 3) at each 0.5 pH unit over the interval
pH 6.0–9.0 are presented in Fig. 1B, indicating a signiﬁcantly increased
VKOR activity (+43%, p b 0.0005 by ANOVA with Fisher's ad hoc
post-test) at pH 6.5 relative to pH 6.0. At pH > 6.5, VKOR activities
were signiﬁcantly lowered by 14% (pH 7.0) to 25% (pH 9.0) of the
pH 6.5 value (p b 0.05 for pH 7.0, p b 0.001 for pH 8.0–9.0).
3.3. Measured warfarin IC50 values for human VKORC1 vary with both K>O
and DTT substrate concentrations—estimates of the warfarin Ki for human
VKORC1 based on IC50 values determined at various substrate concentrations
We measured warfarin dose–response data (85.4 nM to 412.9 μM
warfarin) for DTT-driven VKOR assay conditions holding DTT thiolateFig. 1. Relative VKORC1 enzymatic activities assessed for Ca2+- and pH-dependence.
Panel A shows no signiﬁcant difference betweenVKORC1 activity assessed in the presence
or absence of Ca2+ which has been a standard component of nearly all DTT-driven VKOR
activity assays published to date. Panel B shows relative differences in DTT-driven VKOR
activity for identical samples of VKORC1 assessed at constant DTT thiolate concentration
at various pH values. N = 3 independent measurements for all bars; error bars are ±
SEM; value differences between pairs of bars in each panel are statistically insigniﬁcant
unless indicated by ties (* p b 0.05, **** p b 0.001, ***** p b 0.0005).concentration constant while varying K1>O concentration and, alter-
natively, holding K1>O concentration constant while varying DTT
thiolate concentration. Accordingly, Fig. 2 shows measured warfarin
dose–response data for three different selected assay conditions at
pH 7.5 with either 5 mM DTT (circles; equivalent to 112.3 μM thiolate
or ~0.6⋅Km,DTT) or 0.5 mMDTT (squares; equivalent to 11.2 μM thiolate
or ~0.06⋅Km,DTT), both in the presence of 0.977 μM K>O (equivalent to
~0.8⋅Km,K1>O), and with 5 mM DTT in the presence of 0.296 μM K1>O
(triangles; equivalent to ~0.24⋅Km,K1>O). Four-parameter dose–
response curves were well-ﬁtted to the warfarin dose–response data
as indicated by R2 correlation values ranging from 0.978 to 0.99 (Table
S1, online Supplemental Information). Calculated IC50 values for warfa-
rin inhibition of VKORC1 enzymatic activity using 0.977 μMK1>Owere
6.197 μM at 112.3 μM thiolate and 2.817 μM at 11.23 μM thiolate,
representing a 2.2-fold increase in measured IC50 value when DTT con-
centration was increased from 0.5 mM to 5.0 mM at pH 7.5. The differ-
ence in IC50 values we measured for these conditions is in excellent
agreement with the 2.1-fold theoretical ratio we calculated for IC50
values obtained by substituting the experimentally applied substrate
concentrations and measured Km values into Eq. (1) (see Table S4,
online Supplementary Information). Alternatively, when we lowered
the K1>O substrate concentration, holding DTT thiolate concentration
constant at 112.3 μM, we determined a warfarin IC50 value of
23.62 μM for an initial ` concentration of 0.296 μM. Compared to the
6.197 μM warfarin IC50 for 112.3 μM thiolate and 0.977 μM K1>O, this
represents a 3.8-fold measured increase in IC50 value. Although we cal-
culated only a 1.7-fold theoretical increase in IC50 value for the experi-
mentally applied substrate concentrations and measured Km values
(Table S4, online Supplementary Information), our results are entire-
ly consistent with a predicted increase in the IC50 value at lowered
K1>O concentration while holding thiolate concentration constant.
Substituting the experimentally determined IC50 values (2.817 μM,
6.197 μM, 23.62 μM) together with the corresponding K1>O and
thiolate substrate concentrations and Michaelis constants into
Eq. (1) provides estimates of the VKORC1-intrinsic warfarinFig. 2. Warfarin dose–response data for human VKORC1 measured using three distinct
combinations of K1>O and DTT substrate concentrations at pH 7.5. Mean VKOR activities
for various warfarin concentrations at 5 mM DTT and 0.977 μM K1>O (circles), 0.5 mM
DTT and 0.977 μM K1>O (squares), and 5 mM DTT and 0.296 μM K1>O (triangles); all
data at pH 7.5 for N = 3 independent measurements. Bars indicate ± SEM. Points for
each data set at zero warfarin concentration are valued at 100% activity and included in
the curve-ﬁtting calculations, but are not visible in the plot due to the logarithmic abscissa
scaling. Best-ﬁt four parameter logistical dose–response curves are shown for 5 mM DTT
and 0.977 μM K1>O (solid line, R2 = 0.978, warfarin IC50 6.197 μM), 0.5 mM DTT and
0.977 μM K1>O (dotted line, R2 = 0.991, warfarin IC50 2.871 μM), and 5 mM DTT and
0.296 μM K1>O (dashed line, R2 = 0.982, warfarin IC50 23.672 μM) data.
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tively (Ki mean value 3.628 ± 1.071(SEM) μM, Ki median value
2.633 μM, for the group of three independent determinations).
4. Discussion
4.1. VKORC1 kinetic model and derivation of the IC50–Ki transformation
Cleland previously characterized general kinetic models including
the bi bi ping-pong mechanism that is consistent with previously
reported VKORC1 enzymatics [36]. According to this mechanism,
DTT is ﬁrst bound to the enzyme, reduces active site thiol groups
and is released as the oxidized DTT form. Subsequently, K>O binds
to the active site, oxidizes the active site thiols and is released as
the reduced quinone form of vitamin K allowing another reduced
DTT molecule to bind and repeat the catalytic cycle[13,31]. The initial
steady-state velocity equation describing the in vitro DTT-driven
VKOR bi bi ping-pong mechanism is represented by Eq. (2):
v ¼ V max DTT½  K>O½ 
Km;K>O DTT½  þ Km;DTT K>O½  þ DTT½  K>O½ 
ð2Þ
where v is the experimentally determined initial velocity, Vmax the
maximum velocity of the forward reaction, [DTT] the concentration
of DTT substrate, [K>O] the concentration of vitamin K 2,3-epoxide
substrate, Km,DTT and Km,K>O the true Michaelis constants for sub-
strates DTT and K>O, respectively.
Additionally, Cleland developed kinetic equations for the bi bi
ping-pong mechanism in the presence of various types of inhibitors
[37]. The initial velocity equation for the DTT-driven VKOR assay
with warfarin binding competitive with DTT, but non-competitive
with K>O, is shown as Eq. (3):
v ¼ V max DTT½  K>O½ 
Km;K>O DTT½  þ Km;DTT 1þ IKi
 
K>O½  þ DTT½  K>O½ 
ð3Þ
where I is the concentration of inhibitor (warfarin) and Ki is the asso-
ciated inhibition constant (all other quantities are as previously
deﬁned for Eq. (2)). We next obtained an expression for the concen-
tration of warfarin producing 50% inhibition of VKORC1 (IC50) by set-
ting one-half the right side of Eq. (2) equal to the right side of Eq. (3)
and solving for I. We then set I equal to IC50 to give the IC50–Ki rela-
tionship for Eq. (1) (see Section 2.6). While it is intuitive from
Eq. (1) that the warfarin IC50 value measured will depend on the
concentration of the competitive DTT substrate,3 it is less intuitive
that the experimentally measured IC50 value will also depend on
the concentration of the non-competitive substrate K>O used to
obtain the inhibition data.
4.2. Appropriateness of the bi bi ping-pong kinetic model for studying
VKORC1 function and inhibition by warfarin
Proposal of a kinetic model for an enzyme's function is a necessary
ﬁrst step in designing experiments to biochemically characterize the
catalytic mechanism. The bi bi ping-pong mechanism for VKORC1
was found to be consistent with earlier results of Hildebrandt et al.
and Preusch & Brummet for warfarin-sensitive rat VKORC1.3 There is a difference between total DTT concentration and the effective DTT con-
centration that actually drives VKOR catalysis. Reduction of protein disulﬁdes by the
non-physiological reductant DTT requires sequential deprotonation of both free thiol
groups to produce redox-active thiolate anions. The pKas for these pH-dependent dis-
sociations are 9.2 and 10.1 [52]. The Henderson–Hasselbalch equation is used to calcu-
late the equilibrium concentration of the thiolate forms of DTT at any pH, where each
DTT molecule contributes up to two thiolate moieties—meaning that the sum of
thiolate concentrations for each of the two pKa values is used to calculate the total
thiolate equivalence for any total DTT concentration.Ping-pong kinetics were subsequently veriﬁed for bovine VKORC1 by
Silverman & Nandi [38]. Recently, it was shown that the two conserved
loop cysteines are absolutely required for in vivo VKOR activity[39],
while these are not essential for in vitro DTT-driven VKOR activity
[17,23]. There is evidence that DTT directly interacts with the active
site CXXC motif (human Cys132 and Cys135) to drive the VKOR reac-
tion. Interestingly, the two redox-active loop cysteines (human Cys43
and Cys51) apparently play no direct role in the VKOR reaction, al-
though they are absolutely required for physiological reduction of the
CXXC motif in living cells [23,39]. We assume then that the loop cyste-
ines are chieﬂy maintained in the reduced state by excess DTT used to
drive the in vitro VKOR assay. However, it is reasonable to speculate
that the loop cysteines may be oxidized to transiently form a disulﬁde
by interaction with the active site CXXC motif by a previously charac-
terized disulﬁde relay mechanism [39]. Thus, the potential redox cy-
cling of the loop cysteines may allow the enzyme to sample various
structural conformations important for native-like function.
Early biochemical investigations of rat microsomes revealed that
dicoumarol, warfarin and other 3-substituted 4-hydroxycoumarins
speciﬁcally inhibit VKOR activity [40]. Fasco et al. found that warfarin
binds to and inactivates the oxidized form of VKORC1, although re-
sults by Thijssen & Baars suggest that warfarin binding can be re-
versed in vitro for the reduced form of the enzyme in the presence
of DTT [12,41]. For bovine VKORC1, Silverman & Oliver found that
warfarin is non-competitive4 with respect to the lipidic quinone sub-
strates, conﬁrming earlier observations by Whitlon et al. [9], and that
it is competitive with the in vitro reductant DTT [32].
More recently, Lasseur et al. found that wild-type VKOR activity
from rat liver microsomes showed characteristic enzymatics including
invariance of Km,K1>Owith respect towarfarin concentration and lower-
ing of Vmax in the presence of warfarin, consistent with warfarin inhibi-
tion being non-competitive with respect to K1>O [22]. Hodroge et al.
obtained similar results for wild-type rat VKORC1 heterologously
expressed in the yeast P. pastoris [25].
For the bi bi ping-pong mechanism it is not possible to calculate
any rate constants using the experimentally determined kinetic con-
stants. This is in contrast to the situation for many other enzymatic
mechanisms where rate equations expressed in terms of rate con-
stants can be transformed into equations containing purely terms
that are measurable kinetic constants [36].
The current model assumes that warfarin competes with reduced
DTT for binding to the oxidized form of VKORC1. In the event that war-
farin initially binds to the enzyme to form an enzyme–inhibitor com-
plex that is reversible, there may be applicable forward and reverse
rate constants. Alternatively, in the event that warfarin is activated
by the enzyme to yield a mechanism-based inhibitor (i.e., a covalent
suicide inhibitor that is essentially irreversible) as previously proposed
[42], then only a forward rate constant would be meaningful.4.3. Assay conditions can be adjusted to elucidate various aspects of
VKORC1 function
In the current study we demonstrate that the DTT-driven VKOR
assay conditions can be deﬁned to yield information about the func-
tion of the VKORC1 enzyme. Divalent cations such as Ca2+ might
play a role in stabilizing the lipid membranes that surround the
VKORC1 protein in the assay samples and have historically been
added to assay buffers to stabilize membrane-intrinsic proteins. Spe-
ciﬁcally, we found that Ca2+ does not have a signiﬁcant effect on the
VKOR activity of the human VKORC1 enzyme (Fig. 1A). Thus, CaCl2
could be dispensed with in future studies, if desired.4 Non-comptetitive inhibitors can bind equally to enzyme alone or to the enzyme-
substrate complex and do not affect Km (i.e., do not affect substrate binding), but de-
crease Vmax (inhibitor interferes with catalysis).
5 Recently published studies by Hodroge et al. reported half-maximal dose-response
for warfarin inhibition of VKORC1 enzymes, determined using the DTT-driven VKOR
assay and assuming an enzymatic model with only one substrate (K1>O), as Ki values
[21,25]. However, in light of our current results, these are actually assay condition-
dependent IC50 values, not enzymatic Ki values. Similarly, previous studies by Lasseur
et al. and Choppin et al. erroneously reported warfarin IC50 as Ki [18,22,24,53].
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we were able to measure VKORC1 catalyzed production of the vita-
min K1 quinone product at various pH levels by constraining the
DTT thiolate concentration to a constant value. Accordingly, the
Henderson–Hasselbalch equation was used to calculate the total
amount of DTT at each pH level that results in a constant amount of
the dissociated thiolate form. By this experimental design, we mea-
sured a maximum in VKOR activity for the human VKORC1 enzyme
between pH 6.0 and 7.0 (Fig. 1B). To our knowledge, this is the ﬁrst
report of VKOR activity pH-dependence that is properly corrected
for DTT-thiolate concentration. Consistent with our experimental re-
sults, when we calculated theoretical pH titration curves for human
VKORC1, only the three histidine side chains of the native primary
sequence were found to be titratable over the pH range 5.0 to 7.0
(Fig. S2, online Supplementary Information), suggesting that at least
one surface-exposed histidine with a pKa potentially in the range of
6.0 to 7.0 may be critical for optimal VKOR catalysis by the human
enzyme.
Taking these results together as representative examples strongly
suggests that future studies can now be designed to more ﬁnely
assess various molecular mechanistic aspects of VKORC1 function.
4.4. Warfarin IC50 values determined for VKORC1 by the DTT-driven in
vitro assay vary with substrate concentrations in a manner consistent
with the bi bi ping-pong kinetic model and can be transformed to yield
estimated values for the assay condition-independent Ki constant
We have demonstrated that VKORC1 warfarin inhibition dose–
response data and IC50 values derived from these data are substan-
tially inﬂuenced by a combination of substrate concentrations and
pH when using the DTT-driven in vitro VKOR assay to obtain warfarin
dose–response data (Fig. 2). Accordingly, the Michaelis constant (Km)
values that are intrinsic properties of each particular VKORC1 variant
enzyme (e.g., wild-type or missense mutant) must be carefully deter-
mined in order to correctly transform IC50 values into assay condition-
independent inhibitory constant (Ki) values for comparison of results
between studies. To demonstrate this point, we chose three distinct
combinations of K1>O and DTT thiolate concentrations for collecting
assay data at constant pH. We demonstrated that the respective IC50
values shift to higher or lower values as predicted by Eq. (1). Using
these data, we calculated ﬁrst estimates of the warfarin Ki for human
VKORC1 which, for any choice of actual assay conditions, will strictly
be a lower warfarin concentration value than the measured IC50. Two
of the three estimated warfarin Ki values were in close agreement
(2.481 μM, 2.633 μM) when K1>O concentration was held constant
and DTT thiolate concentration altered, while the third estimate was
somewhat greater (5.768 μM) when the K1>O concentration was
decreased while holding the DTT thiolate concentration constant
(Table S4, online Supplementary Information). Since we used the
same substrate stock solutions for all measurements in this study, the
later discrepancy in estimated Ki value suggests that our determination
of Km,Thiolate was less accurate than that of Km,K1>O, leading to estima-
tion of a greater Ki value than it actually would be if the value we
used for Km,Thiolate in Eq. (1) were slightly larger. The fact that, of the
two very similar Ki values obtained at constant K1>O concentration,
the 2.633 μM value for the greater DTT thiolate concentration is some-
what greater than the 2.481 μM value for the lower thiolate concentra-
tion also supports this notion as using the third assay condition with
lower K1>O concentration would be expected to further exacerbate
the increased offset in measured IC50 and, hence, also in Ki value esti-
mated by the Eq. (1) transformation.
Another experimental uncertainty that could contribute to the
larger Ki outlier may be that our inhibitory dose–response data was
relatively sparser in the warfarin concentration range close to the
IC50 value for the third assay condition, whereas data for warfarin
concentrations were assessed close to the IC50 values determinedfor the ﬁrst two assay conditions (Fig. 2). In order to better deﬁne
the ﬁtted dose–response curve for this data series, we measured addi-
tional assay samples at a warfarin concentration of 76.75 μM, closer
to the resulting IC50. This underscores the importance of collecting
dose–response data near to the IC50 value being measured—a data
collection requirement that cannot be optimized a priori, but must
be optimized by careful observation and, when necessary, additional
experimental measurements.
We expect that future investigations will reconﬁrm our results
and provide new data for Michaelis kinetic constants and warfarin
inhibition Ki for VKORC1 variants including missense mutations asso-
ciated with warfarin resistance. If Ki values measured for warfarin in-
hibition of warfarin resistance-associated human and rodent VKORC1
missense variants using the present method are found to be greater
than Ki for the respective wild-type enzymes, we would expect dif-
ferences in both K>O and DTT Michaelis constants for the variants,
relative to those of the wild-type enzymes, to be fundamentally re-
sponsible for differences in Ki values. Recently, Hodroge et al. deter-
mined an almost 20-fold variation in Km for the K1>O substrate
among 15 warfarin resistance-associated human VKORC1 variants
for which they could measure DTT-driven VKOR activity [21]. How-
ever, only four of these variants were determined to be warfarin re-
sistant as assessed by IC50 measurements.5 Additionally, they could
measure sufﬁcient VKOR activity to determine enzymatic and warfa-
rin inhibitory parameters for only nine out of the 19 expressed
naturally-occurring VKORC1 missense variants due to low basal
VKOR activity levels measured by the DTT-driven assay. For the ten
variants with low or undetectable VKOR activity, we are tempted to
speculate that one or perhaps both of the Michaelis constants may
be much greater than the substrate concentrations used in their
standard assay (3–200 μM K1>O; 1 mM DTT pH 7.4, equivalent to
18 μM DTT-thiolate). Thus, making assay measurements at much
higher DTT and/or K1>O substrate concentrations may alleviate
this problem when VKORC1 variants with mutations are found to
have greater than wild-type Km values and VKOR basal activity is
found to be low by the standard assay conditions. However, care
must also be taken to ensure that signiﬁcant product inhibition
does not confound VKOR assay measurements by restricting initial
substrate concentrations to levels for which the amount of substrate
K>O converted to product K quinone during the course of the assay
(1 h for the present study) is ≤5% of the initial amount of substrate.4.5. A retrospective analysis of previously reported assay conditions
and IC50 results is consistent with our current understanding of the
DTT-driven VKOR assay
Wecompared our assay conditions andmeasured IC50 results to those
from previous studies (Table S1, online Supplemental Information).
In general agreement with Eq. (1) representing the theoretical relation-
ship between IC50 and Ki, we found that thewarfarin IC50 values reported
for human and rat ortholog enzymes (0.5–4.0 μM) varied monotonically
with DTT thiolate concentration (16–220 μM; see Table S1, c.f. colored
entries under columns labeled “[Thiolate] (μM)” and “IC50 (μM)”).
Additionally, we note that all of the retrospective studies used K1>O sub-
strate concentrations much greater than Km,K1>O and, hence, differences
in K1>O concentrations had little inﬂuence on the ranking of the respec-
tive IC50 values determined. As both accurately determined Michaelis
constants (Km,Thiolate, Km,K1>O) are required for complete assessment of
the apparent warfarin inhibition constant (Ki), we cannot retrospectively
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fortunately, the warfarin IC50 values are not comparable between previ-
ous studies.
4.6. Advantages and caveats of using the DTT-driven VKOR assay
A practical advantage of studying VKORC1 enzymatics and warfarin
inhibition using the DTT-driven VKOR in vitro assay is having complete
control over which components are present and at what concentra-
tions. Such deﬁned conditions are never attainable in in vivo or cell
culture-based in vitro assay systems. However, results from both types
of VKOR assay systems should ultimately be in agreement and each
type of assay can be used to investigate aspects of enzymatic function
not necessarily approachable by the other.
Another advantage to the experimental system in the current
study lies in the use of heterologously expressed VKORC1 variants
in P. pastoris membranes for which there is a complete absence of
endogenous expression of VKOR and other enzymes involved in vita-
min K metabolism and the vitamin K cycle [43,44]. Thus, our assay
system allows assessment of VKOR activity data uncomplicated byFig. 3. A ﬂow diagram showing the relationships between raw enzyme activity data obtained
conditions and enzymatic constants (grey-ﬁlled boxes) necessary for transformation (second
assay-independent inhibition constant Ki (bottom black box). Experimentally determine
blue-to-yellow gradient) showing how individually determined IC50 values (represented
concentrations. Substrate concentrations shown for convenience in units of Km values (hor
IC50 value, the transformation (equation in second box from bottom) results in estimates
assay substrate concentrations. Unlike for many other enzyme/inhibitor pairs, there is no p
experimentally measured warfarin IC50 for VKORC1 is directly equal to the warfarin Ki. Im
each warfarin resistance-associated VKORC1 missense variant in order to accurately establiadditional vitamin K-dependent enzymatic pathways. Furthermore,
the major electron transport quinone for the Pichia respiratory
chain, ubiquinone-8 (Q8), is present in the VKORC1-containing
membranes and is not a substrate for VKORC1 [45]. Since Q8 absorbs
considerably at the 248 nmwavelengthwe used for K vitamer detec-
tion and its elution peak (8.10–8.20 min retention time) is well re-
solved from the K1 (9.34–9.37 min) and K1>O (7.00–7.05 min)
peaks, our system provides the possibility to use the endogenous
Q8 as an internal standard for assessment of quality control in data
collection and for detecting and normalizing the amount of enzyme
for pipetting errors from initial addition of assay components though
transfer of organic solvent-extracted products from the assay to the
HPLC system for analysis.
Fig. 3 summarizes the most important conclusion from this study
—IC50 values obtained by the DTT-driven VKOR assay must not be
simply interpreted as equivalent to the kinetic inhibition constant
Ki. As revealed by our present results and analysis, the IC50 values
obtained from warfarin dose–response experiments require transfor-
mation by Eq. (1) in order to evaluate the apparent inhibition con-
stant (Ki). As warfarin inhibition of VKORC1 is non-competitive withby the in vitro DTT-driven VKOR assay (upper heavy-lined black box), measured assay
box from bottom) of the VKOR assay-dependent inhibitor IC50 (center of ﬁgure) to the
d warfarin dose–response data (center right) map onto a 3D-surface (colored as a
by black points on the 3D-surface) can vary for different combinations of substrate
izontal axes of 3D-plot); IC50 (vertical axis) in units of Ki,. In theory, for any measured
of just one unique Ki constant for each enzyme variant studied, independent of the
ractical combination of K1>O and DTT thiolate substrate concentrations for which the
portantly, both Michaelis constants must be determined for wild-type as well as for
sh the respective transformation between IC50 and Ki values in each case.
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with the DTT substrate, measured IC50 is strictly not equivalent to Ki
[30]. However, comparison of IC50 values can still be validly assessed
between studies when only one particular VKORC1 variant is consid-
ered for a particular inhibitor and the assay conditions are identical.
Comparison of IC50 values among different enzyme variants or
among different inhibitors has no interpretable meaning.
5. Conclusions and future perspectives
Our primary motivation for investigating the DTT-driven VKOR
assay was to shown that the warfarin Ki, an enzyme-dependent
biochemical constant that objectively reports inhibition of VKOR
enzymes by warfarin, can be determined once several parameters
have been measured including the two enzyme-speciﬁc Michaelis
constants for K>O and DTT-thiolate substrates, the assay condition-
speciﬁc DTT-thiolate and K>O substrate concentrations, and the assay
condition-speciﬁc IC50 value (Fig. 3). Additionally, Ki values for
other VKORC1 inhibitors besides warfarin can now be determined
and objectively compared between studies. Currently, these include
three known chemically diverse families of direct VKORC1 inhibitors
—3-substituted 4-hydoxycoumarins for which warfarin is the chief
representative human oral anticoagulant[28,46,47], 2-substituted
indane-1,3-diones chieﬂy represented by ﬂuindione, used primarily in
francophone countries[48,49]; and recently identiﬁed 5-substituted
3-acetyltetronic acids [50].
The ability to determine inhibitor Ki values for VKORC1 from ex-
perimentally determined DTT-driven VKOR activity inhibition data
under deﬁned assay conditions in vitro will enable standardized
in vitro investigation and characterization of the 25 currently known
human VKORC1 missense mutation variants associated with oral an-
ticoagulant resistance [20]. If the Ki values will reﬂect the relative
differences in in vivo therapeutic warfarin dosage requirements in
patients harboring such mutations remains to be demonstrated.
An even larger number of rodent VKORC1 variants associated with
resistance to second and third generation rodenticides can now also
be comparatively investigated [16,19]. For assessment of rodenticide
efﬁcacy, the Ki values determined for wild-type and missense VKORC1
variants associated with rodenticide resistance may be expected to
follow trends in in vivo LD50 values.
Finally, the same assay and analytical methods, but substituting
vitamin K for K>O as substrate, can be used to investigate warfarin
and other oral anticoagulant inhibition of vitamin K reductase
(VKR) activity, a second reaction catalyzed by both VKORC1[23] and
the vertebrate paralog enzyme VKORC1L1 [51]. In this case, product
inhibition is not as great a concern as for the VKOR reaction, so the
amount of substrate converted over the time course of the assay is
not as critical.
We anticipate that future studies will extend the present results
with the aim of conﬁrming if in vitro assessed inhibitor Ki values for
human and rodent oral anticoagulant resistance-associated VKORC1
missense variants are, in fact, in agreement with the respective
in vivo resistance phenotypes. We also envision the application of
the current methods in conjunction with site-directed mutagenesis
as a powerful tool for elucidating the molecular details of VKORC1
catalytic and inhibitory mechanisms.
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